{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:16:41Z","timestamp":1790072201306,"version":"4.0.1"},"reference-count":46,"publisher":"Impact Journals, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,4,30]]},"DOI":"10.18632\/oncotarget.3230","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T06:35:44Z","timestamp":1442298944000},"page":"10510-10520","source":"Crossref","is-referenced-by-count":35,"title":["HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status"],"prefix":"10.18632","volume":"6","author":[{"given":"Wen-Bin","family":"Ou","sequence":"first","affiliation":[{"name":"College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, China"},{"name":"Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, Zhejiang, China"},{"name":"Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Zhu","sequence":"additional","affiliation":[{"name":"College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Eilers","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Li","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Kuang","sequence":"additional","affiliation":[{"name":"College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Mari\u00f1o-Enr\u00edquez","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqin","family":"Yan","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Li","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanguo","family":"Meng","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Sheng","sequence":"additional","affiliation":[{"name":"College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,3,23]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jso.20975","article-title":"Diagnosis and management of lipomatous tumors","volume":"97","author":"Singer","year":"2008","journal-title":"J Surg Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"16386","DOI":"10.1073\/pnas.1106127108","article-title":"Aberrant AKT activation drives well-differentiated liposarcoma","volume":"108","author":"Wagner","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/CCO.0b013e32834796e6","article-title":"Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma","volume":"23","author":"Singer","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2214\/ajr.164.1.7998525","article-title":"Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location","volume":"164","author":"Kransdorf","year":"1995","journal-title":"AJR Am J Roentgenol"},{"key":"5","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1016\/j.ejca.2005.07.023","article-title":"Differential sensitivity of liposarcoma subtypes to chemotherapy","volume":"41","author":"Judson","year":"2005","journal-title":"Eur J Cancer"},{"key":"6","first-page":"483154","article-title":"Liposarcoma: molecular genetics and therapeutics","volume":"2011","author":"Thomas","year":"2011","journal-title":"Sarcoma"},{"key":"7","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/ijc.23380","article-title":"HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon","volume":"122","author":"Terrier","year":"2008","journal-title":"Int J Cancer"},{"key":"8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ijc.22685","article-title":"Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the \u201cmissing link\u201d between lipomas and liposarcomas?","volume":"121","author":"Pedeutour","year":"2007","journal-title":"Int J Cancer"},{"key":"9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00428-012-1256-5","article-title":"A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11\u201314 regions","volume":"461","author":"Coindre","year":"2012","journal-title":"Virchows Arch"},{"key":"10","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1097\/PAS.0b013e3180581fff","article-title":"Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR","volume":"31","author":"Pedeutour","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ng.619","article-title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","volume":"42","author":"Mermel","year":"2010","journal-title":"Nat Genet"},{"key":"12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/path.2564","article-title":"c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme","volume":"218","author":"Fletcher","year":"2009","journal-title":"J Pathol"},{"key":"13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/modpathol.2011.148","article-title":"Involvement of the PI3K\/Akt pathway in myxoid\/round cell liposarcoma","volume":"25","author":"Lazar","year":"2012","journal-title":"Mod Pathol"},{"key":"14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/CCO.0b013e32836227ac","article-title":"Myxoid liposarcoma and the mammalian target of rapamycin pathway","volume":"25","author":"Casali","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1560","article-title":"The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas","volume":"13","author":"Cordon-Cardo","year":"2007","journal-title":"Nat Med"},{"key":"16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cell.2009.04.050","article-title":"Modes of p53 regulation","volume":"137","author":"Gu","year":"2009","journal-title":"Cell"},{"key":"17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1096-9896(199701)181:1<14::AID-PATH730>3.0.CO;2-O","article-title":"Distinct mdm2\/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms","volume":"181","author":"Pierotti","year":"1997","journal-title":"J Pathol"},{"key":"18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2350\/09-08-0694-OA.1","article-title":"p53+\/mdm2-atypical lipomatous tumor\/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome","volume":"13","author":"Kozakewich","year":"2010","journal-title":"Pediatr Dev Pathol"},{"key":"19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ijc.22643","article-title":"Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A","volume":"121","author":"Myklebost","year":"2007","journal-title":"Int J Cancer"},{"key":"20","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1158\/0008-5472.CAN-07-0584","article-title":"Gene expression profiling of liposarcoma identifies distinct biological types\/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma","volume":"67","author":"Antonescu","year":"2007","journal-title":"Cancer Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Chabner","year":"2009","journal-title":"J Clin Oncol"},{"key":"22","first-page":"241","article-title":"Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer","volume":"1815","author":"Gulino","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"Johnstone","year":"2014","journal-title":"J Clin Invest"},{"key":"24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2164-7-90","article-title":"Differential expression of selected histone modifier genes in human solid cancers","volume":"7","author":"Kouzarides","year":"2006","journal-title":"BMC Genomics"},{"key":"25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.lungcan.2011.02.019","article-title":"Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung","volume":"74","author":"Ogawa","year":"2011","journal-title":"Lung Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1158\/1078-0432.CCR-07-0990","article-title":"Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylasesand","volume":"14","author":"Denkert","year":"2008","journal-title":"Clin Cancer Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Kristiansen","year":"2008","journal-title":"Br J Cancer"},{"key":"28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1471-2407-13-215","article-title":"Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression","volume":"13","author":"Denkert","year":"2013","journal-title":"BMC Cancer"},{"key":"29","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Duvic","year":"2007","journal-title":"J Clin Oncol"},{"key":"30","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Kim","year":"2010","journal-title":"J Clin Oncol"},{"key":"31","doi-asserted-by":"crossref","first-page":"7386","DOI":"10.1158\/0008-5472.CAN-04-3433","article-title":"Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors","volume":"65","author":"Fojo","year":"2005","journal-title":"Cancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4161\/cbt.317","article-title":"The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53","volume":"1","author":"Blagosklonny","year":"2002","journal-title":"Cancer Biol Ther"},{"key":"33","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/cdd.2011.71","article-title":"SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis","volume":"18","author":"Moll","year":"2011","journal-title":"Cell Death Differ"},{"key":"34","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1541-7786.MCR-10-0534","article-title":"Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells","volume":"9","author":"Moll","year":"2011","journal-title":"Mol Cancer Res"},{"key":"35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P","article-title":"Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors","volume":"24","author":"Turc-Carel","year":"1999","journal-title":"Genes Chromosomes. Cancer"},{"key":"36","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma","volume":"31","author":"Singer","year":"2013","journal-title":"J Clin Oncol"},{"key":"37","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.ajpath.2013.01.002","article-title":"Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition","volume":"182","author":"Wu","year":"2013","journal-title":"Am J Pathol"},{"key":"38","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Fletcher","year":"2014","journal-title":"Br J Cancer"},{"key":"39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jep.2011.04.034","article-title":"NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells","volume":"136","author":"Chen","year":"2011","journal-title":"J Ethnopharmacol"},{"key":"40","article-title":"Combination inhibition of the FAK-p53and MDM2-p53interactions suppressed proliferation inmesothelioma","volume":"70","author":"Fletcher","year":"2010","journal-title":"Cancer Res"},{"key":"41","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ejca.2011.11.009","article-title":"Vorinostat\/SAHA-induced apoptosis in malignant mesothelioma is FLIP\/caspase 8-dependent and HR23B-independent","volume":"48","author":"Fennell","year":"2012","journal-title":"Eur J Cancer"},{"key":"42","first-page":"148614","article-title":"Characterization of liposarcoma cell lines for preclinical and biological studies","volume":"2012","author":"Myklebost","year":"2012","journal-title":"Sarcoma"},{"key":"43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1593\/neo.101156","article-title":"Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma","volume":"13","author":"Fletcher","year":"2011","journal-title":"Neoplasia"},{"key":"44","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood.V74.3.940.940","article-title":"Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines","volume":"74","author":"Griffin","year":"1989","journal-title":"Blood"},{"key":"45","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/onc.2010.555","article-title":"AXL regulates mesothelioma proliferation and invasiveness","volume":"30","author":"Fletcher","year":"2011","journal-title":"Oncogene"},{"key":"46","first-page":"8118","article-title":"KIT Activation Is a Ubiquitous Feature of Gastrointestinal Stromal Tumors","volume":"61","author":"Fletcher","year":"2001","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T10:47:25Z","timestamp":1589366845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.3230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,23]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,4,30]]}},"alternative-id":["3230","25888633"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.3230","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,23]]}}}